Correlation of 18F-fluorodeoxyglucose positron emission tomography/computed tomography related parameters with the degree of proliferation in lung adenocarcinoma
- PMID: 40594300
- PMCID: PMC12215422
- DOI: 10.1038/s41598-025-05165-z
Correlation of 18F-fluorodeoxyglucose positron emission tomography/computed tomography related parameters with the degree of proliferation in lung adenocarcinoma
Abstract
The objective of this study was to evaluate the correlation between positron emission tomography/computed tomography (PET/CT) parameters and the degree of proliferation of lung adenocarcinoma. A retrospective analysis was conducted on 50 patients who had undergone surgical treatment for lung adenocarcinoma and had been subsequently diagnosed pathologically. The general clinical characteristics of the subjects were documented, and the presurgical 2-deoxy-2-fluorine-18-fluoro-D-glucose 18F-FDG) PET/CT-related parameters were quantified or calculated, including age, gender, maximum standardised uptake value (SUVmax), mean standard(ised uptake value (SUVmean), total lesion glycolysis (TLG), tumour metabolic volume (MTV), and maximum tumour mediastinal background ratio (SUVtmr). The correlation between each parameter and the tumour Ki-67 expression level was assessed using two grouping methods. The results demonstrated that there was no statistically significant difference in SUVmax, SUVmean, and SUVtmr between the Ki-67 (++) group (10% < Ki-67 ≤ 50%) and the Ki-67(+++)(Ki-67 > 50%) group. This difference was only observed between the Ki-67(+) group (Ki-67 ≤ 10%) and the Ki-67(++) group, as well as between the Ki-67(+) group and the Ki-67(+++) group. When grouping was less distinct, PET/CT-related parameters between the low expression level group (Ki-67 ≤ 10%) and the high Ki-67 expression level group (Ki-67 > 10%) were statistically significant. This study found that PET/CT-related parameters, particularly SUVmax, SUVmean, and SUVtmr, were not effective in accurately distinguishing between the lung adenocarcinoma Ki-67(++) (10% < Ki-67 ≤ 50%) and Ki-67(+++) (Ki-67 > 50%) groups.
Keywords: Adenocarcinoma of lung; Ki-67 antigen; Positron-emission tomography.
© 2025. The Author(s).
Conflict of interest statement
Declarations. Competing interests: The authors declare no competing interests.
Figures
Similar articles
-
Characterization of Pulmonary Sclerosing Pneumocytoma Assessed by 18F-FDG PET/CT.Thorac Cancer. 2025 Jul;16(13):e70124. doi: 10.1111/1759-7714.70124. Thorac Cancer. 2025. PMID: 40623844 Free PMC article.
-
Relationship between PD-L1 expression and [18F]FAPI versus [18F]FDG uptake on PET/CT in lung cancer.Eur J Nucl Med Mol Imaging. 2025 Jul;52(9):3211-3222. doi: 10.1007/s00259-025-07201-6. Epub 2025 Mar 21. Eur J Nucl Med Mol Imaging. 2025. PMID: 40113644
-
FDG PET/CT metabolic tumor volume and total lesion glycolysis predict prognosis in patients with advanced lung adenocarcinoma.J Cancer Res Clin Oncol. 2014 Jan;140(1):89-98. doi: 10.1007/s00432-013-1545-7. Epub 2013 Nov 6. J Cancer Res Clin Oncol. 2014. PMID: 24194352 Free PMC article.
-
Fluorine-18-fluorodeoxyglucose (FDG) positron emission tomography (PET) computed tomography (CT) for the detection of bone, lung, and lymph node metastases in rhabdomyosarcoma.Cochrane Database Syst Rev. 2021 Nov 9;11(11):CD012325. doi: 10.1002/14651858.CD012325.pub2. Cochrane Database Syst Rev. 2021. PMID: 34753195 Free PMC article.
-
Prognostic value of 18F-FDG-PET/CT parameters in patients with pancreatic carcinoma: A systematic review and meta-analysis.Medicine (Baltimore). 2017 Aug;96(33):e7813. doi: 10.1097/MD.0000000000007813. Medicine (Baltimore). 2017. PMID: 28816978 Free PMC article.
References
-
- Siegel, R. L., Miller, K. D., Fuchs, H. E. & Jemal, A. Cancer statistics, 2022. CA Cancer J. Clin.72, 7–33 (2022). - PubMed
-
- Hrinczenko, B., Subramonia-Iyer, S., Zhang, D. & Olsen, B. Adequacy of biopsy samples for molecular testing in patients with non-small cell lung cancer. J. Clin. Oncol.30, e21133–e21133 (2012).
-
- Kirienko, M. et al. Ability of FDG PET and CT radiomics features to differentiate between primary and metastatic lung lesions. Eur. J. Nucl. Med. Mol. Imaging. 45, 1649–1660 (2018). - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical